Researchers at Stanford and UCSF have discovered a strong association between serious, potentially fatal, delayed hypersensitivity reactions that occur in a subset of patients exposed to IL-1/IL-6 inhibitors and HLA-DRB1*15 alleles that are common across ancestries.
Researchers at Stanford previously described a method under Stanford Docket S17-020 for introducing a large number of gene edits in parallel, termed Multiplexed Accurate Genome Editing with Short, Trackable, Integrated Cellular barcodes (MAGESTIC).
Researchers at Stanford and the European Molecular Biology Laboratory (EMBL) have discovered an improved embodiment of bacterial retron-based CRISPR gene editing in mammalian cells.
Stanford researchers have developed a geometric deep learning based novel method to aid in identification and discovery of novel drug scaffolds as well as to optimize known scaffolds, as a means to combat the major challenge in drug discovery.
Stanford researchers at Dr. Williams' Brain Stimulation Lab have developed a method to treat brain disorders such as traumatic brain injury using a naturally occurring psychoactive molecule found in plants called Ibogaine.
Stanford and Baylor researchers have discovered an exercise-induced lactate-derived metabolite that mediates the anorexigenic and anti-obesity effects of physical activity.
Researchers at Stanford University have discovered that the absence of a long non coding RNA (lnc122) predisposed mice to high numbers of hepatocellular carcinomas (HCC), and its replacement decreased the risk of HCC.
Stanford inventors have created a novel, interactive, highly scalable computational approach for representing dynamic brain activity as a network for use in clinical settings.
To combat the growing problem of antibiotic resistant bacteria, Stanford researchers have developed nanoclusters comprising a metallic core conjugated to a nucleotide.
One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.
Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2.